- Home
- ANTA vs EDIT Comparison
ANTA vs EDIT Comparison
Compare ANTA & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANTA | EDIT |
|---|---|---|
| Founded | 2022 | 2013 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.5M | 202.1M |
| IPO Year | 2025 | 2016 |
Fundamental Metrics
Financial Performance| Metric | ANTA | EDIT |
|---|---|---|
| Price | $9.00 | $2.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $17.50 | $4.50 |
| AVG Volume (30 Days) | 4.5K | ★ 1.9M |
| Earning Date | 11-10-2025 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 669.18 | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $65,033,103.00 | $46,383,000.00 |
| Revenue This Year | $69.27 | N/A |
| Revenue Next Year | $64.32 | N/A |
| P/E Ratio | $19.24 | ★ N/A |
| Revenue Growth | ★ 63.28 | N/A |
| 52 Week Low | $8.50 | $0.91 |
| 52 Week High | $27.72 | $4.54 |
Technical Indicators
Market Signals| Indicator | ANTA | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 43.30 | 57.05 |
| Support Level | $9.00 | $1.92 |
| Resistance Level | $9.99 | $2.28 |
| Average True Range (ATR) | 0.31 | 0.15 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 22.59 | 86.24 |
Price Performance
Historical ComparisonAbout ANTA Antalpha Platform Holding Company Ordinary Shares
Antalpha Platform Holding Co provides financing, technology and risk management solutions to the digital asset industry. It is a provider of supply chain financing solutions to institutional and corporate participants in the Bitcoin mining industry, offering loans secured by Bitcoin and Bitcoin mining machines. It has developed a technology platform, Antalpha Prime, which enables customers to apply for and manage their digital asset loans while allowing to closely monitor collateral positions.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.